|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0显示文摘AIM: To develop a new sensitive and inexpensive hepatitis C virus (HCV) combination test (HCV Guideline test) that enables the determination of HCV genotypes 1, 2 and 3,and simultaneous determination of HCV viral load using commercial Amplicor GT HCV MONITOR test v2.0 (microwell version).METHODS: The HCV Guideline test used the PCR product generated in commercial Amplicor GT HCV Monitor test v2.0 for viral load measurement using microwell plate version of Amplicor HCV Monitor and also captured on separate plates containing capture probes and competitive oligonucleotide probes specific for HCV genotypes 1, 2 and 3, The HCV genotype was subsequently determined using the biotin-labeled PCR product and five biotin-labeled HCV-specific probes.RESULTS: The sensitivity of the HCV Guideline test was 0.5 KIU/mL. Specificity of the HCV Guideline test was confirmed by direct sequencing of HCV core region and molecular evolutionary analyses based on a panel of 31 samples. The comparison of the HCV Guideline test and an in-house HCV core genotyping assay using 252 samples from chronic hepatitis C patients indicated concordant results for 97.2% of samples (59.5% genotype 1, 33.7% genotype 2, 6.0% genotype 3, and 0.8% mixed genotypes).Similarly, the HCV Guideline test showed concordance with a serological test, and the serological test failed to assign any serotype in 12.7% of the samples, indicating a better sensitivity of the HCV Guideline test.CONCLUSION: Clinically, both viral load and genotypes (1, 2 and 3) have been found to be major predictors of antiviral therapy outcome regarding chronic hepatitis C based on guidelines and they are, in normal circumstances,performed as separate stand-alone assays. The HCV Guideline test is a useful method for screening large cohorts in a routine clinical setting for determining the treatment regimen and for predicting the outcome of antiviral therapy of chronic hepatitis C. | Motokazu Mukaide Yasuhito Tanaka Hirokazu Kakuda Kei Fujiwara Fuat Kurbanov Eturo Orito Kentaro Yoshioka Kiyotaka Fujise Shoji Harada Takazumi Kozaki Kazuo Takemura Kazumasa Hikiji Masashi Mizokami | 2005 | World Journal of Gastroenterology2005，11，4： | 3 |
| 2 | Analyses of Expression of Cytoglobin by Immunohistochemical Studies in Human Tissues显示文摘 | Akio Shigematsu Yasushi Adachi Junko Matsubara Hiromi Mukaide Naoko Koike-Kiriyama Keizo Minamino Ming Shi Seiji Yanai Masahiro Imamura Shigeru Taketani Susumu Ikehara | 2008 | Hemoglobin2008，，3： | 1 |
| 3 | Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation 显示文摘 | Mukaide M Tanaka Y Shin-I T | 2010 | Antimicrob Agents Chemother2010，54，2： | 1 |
| 4 | Inhibition of neutrophil mechated acute inflammation injury by an antibody against interleukin ( IL-8 ) 显示文摘 | Mukaide N Mastumoto T Yokoi K | 1998 | Inflammation Res1998，47，3： | 1 |
| 5 | High pressure and high temperature phase transformations in LiNbO3显示文摘 | Mukaide T Miyajima N Kondo T | 2003 | Journal of Applied Physics2003，93，7： | 1 |
| 6 | Stimulation of interleukin-8 production by acidic polysaccharide from the root of Panax Ginseng显示文摘 | Kasahara T Mukaide N | 1998 | Immunopharmacol1998，38，3： | 1 |
| 7 | FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma显示文摘 | Mukaide H Adachi Y Taketani S Iwasaki M Kotke-Kiriyama N Shigematsu A | 2008 | Cancer Invest2008，26，： | 1 |
| 8 | Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation显示文摘 | Mukaide M Tanaka Y Shin-1 T | 2010 | Antimicrob Agents Chemother2010，54，2： | 1 |
| 9 | Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma 显示文摘 | Tanaka Y Mukaide M Orito E | 2006 | J Hepatol2006，45，5： | 1 |
| 10 | Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation显示文摘 | Mukaide M Tanaka Y Shin-I T | 2010 | Antimicrob Agents Chemother2010，54，2： | 1 |
| 11 | Inhibition of neutrophil mediated acute inflammation injury by an antibody against interleukin-8(IL-8)显示文摘 | Mukaide N Matsumoto T Yokoi | 1998 | Inflammation Res1998，，13： | 1 |
| 12 | Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns显示文摘 | Masashi Mizokami Tatsunori Nakano Etsuro Orito Yasuhito Tanaka Hiroshi Sakugawa Motokazu Mukaide Betty H. Robertson | 1999 | FEBS Letters1999，，1： | 1 |
| 13 | Inhibition of neutrophil mediated acute inflammation injury by an antibody against interleukin-8 (IL-8) 显示文摘 | Mukaide N Matsumoto T Yokoi K | 1998 | Inflamm Res1998，47，3： | 1 |
| 14 | A patient with diffuse peritineal meastases of GIST who was administered ST1571 显示文摘 | Mukaide H Hasuike Y Takeda Y | 2002 | Gan To Kagaku Ryoho2002，29，： | 1 |
| 15 | Specific mutations in enhancer Ⅱ/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma显示文摘 | Tanaka Y Mukaide M Orito E | 2006 | J Hepatol2006，45，5： | 1 |
| 16 | Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma显示文摘 | Yasuhito Tanaka Motokazu Mukaide Etsuro Orito Man-Fung Yuen Kiyoaki Ito Fuat Kurbanov Fuminaka Sugauchi Yasuhiro Asahina Namiki Izumi Michio Kato Ching-Lung Lai Ryuzo Ueda Masashi Mizokami | 2006 | Journal of Hepatology2006，，5： | 1 |
| 17 | Specific mutations in enhancer Ⅱ/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma 显示文摘 | Tanaka Y Mukaide M Orito E | 2006 | J Hepatol2006，45，5： | 1 |
| 18 | FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma显示文摘 | Mukaide H Adachi Y Taketani S | | 0，，04： | 1 |
| 19 | Inhibition of neutrophil mediated acute inflammation injury by and antibody against interleukin - 8 (IL- 8) 显示文摘 | Mukaide N Matsumoto T Yoloi | 1998 | Inflammation Res1998，47，3： | 1 |
| 20 | Specific mutations inenhancer ll/core promoter of hepatitis B virus subgenotypesC1/C2 increase the risk of hepatocellular carcinoma 显示文摘 | Tanaka Y Mukaide M Orito E | 2006 | JHepatol2006，45，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员